Rallybio Corporation's SEC filings document material events for a clinical-stage biotechnology issuer developing rare-disease therapies in complement dysregulation and hematology. Its 8-K disclosures cover operating and financial results, clinical or regulatory updates, material agreements, and capital-structure matters tied to its common stock.
The filing record also includes stockholder voting results and governance disclosures, including certificate-of-incorporation amendments, reverse stock split disclosure, Nasdaq Capital Market listing matters, and registered common stock information. Agreement filings describe transactions involving Rallybio IPB, LLC, RE Ventures I, LLC, Recursion and the REV102 ENPP1 program, alongside emerging-growth-company reporting status and other material-event disclosures.
Rallybio (RLYB) filed its Q3 2025 10‑Q reporting a swing to profitability driven by a joint‑venture sale. The company recorded net income of $16.0 million for the quarter, reflecting $22.5 million of total other income including a $22.4 million gain on the sale of its REV102 JV interest. Core operations remained loss‑making with loss from operations of $6.9 million as R&D fell to $4.1 million and G&A to $3.0 million. Revenue from collaboration and license activities was $212 thousand.
Cash, cash equivalents and marketable securities were $59.3 million as of September 30, 2025. Management states these resources are expected to fund operations for more than 12 months, and elsewhere indicates funding sufficiency through 2027. Weighted‑average shares outstanding were 45,058,591 for the quarter; shares outstanding were 42,243,774 as of October 31, 2025.
The lead asset RLYB116 advanced with a confirmatory PK/PD multiple‑dose study underway; top‑line data are anticipated in Q4 2025. The company discontinued the RLYB212 program in April 2025 and completed a workforce reduction in May 2025 to focus resources on RLYB116 and preclinical programs.
Rallybio Corporation (RLYB) furnished an 8-K stating it issued a press release announcing financial results for the quarter ended September 30, 2025. The press release is included as Exhibit 99.1.
The company noted that the information in Item 2.02, including Exhibit 99.1, is furnished and not deemed “filed” under the Exchange Act, which limits potential liability and incorporation by reference unless specifically stated.
Rallybio Corporation received an additional grace period from Nasdaq to fix a share price problem that threatens its stock market listing. After its common stock traded below the required $1.00 minimum closing bid price for 30 straight business days and failed to recover by the initial August 25, 2025 deadline, Nasdaq approved the company’s transfer from the Nasdaq Global Select Market to the Nasdaq Capital Market.
The transfer took effect at the opening of business on August 29, 2025, and the stock continues to trade under the symbol “RLYB”. Rallybio now has until February 23, 2026 to regain compliance with Nasdaq’s bid price rule. The company plans to monitor its share price and is considering options to restore compliance, including a potential reverse stock split if needed.
If Rallybio does not meet the minimum bid price requirement by the new deadline, Nasdaq may move to delist the stock, although the company would have the right to appeal that decision to a Nasdaq Hearings Panel.
Rallybio Corporation (NASDAQ: RLYB) has divested its 50 % ownership in RE Ventures I, LLC (the ENPP1 joint venture) to Recursion Pharmaceuticals for immediate and potential future consideration.
- Initial consideration: Recursion issued 1,457,952 Class A shares (VWAP $5.1442) valued at $7.5 million on 8 July 2025.
- Make-whole mechanism: If Rallybio’s net proceeds from selling the Initial Shares differ from $7.5 million, the party benefiting must true-up the difference in cash.
- Contingent equity: Upon achievement of specified development milestones for the ENPP1 compound, Rallybio may receive additional shares worth up to $12.5 million, with the same make-whole feature.
- Milestone & royalty stream: The agreement grants Rallybio undisclosed cash milestone payments and low-single-digit royalties on future net sales of ENPP1-related products.
- Following the sale, the ENPP1 JV becomes an indirect wholly-owned subsidiary of Recursion; Rallybio relinquishes all equity interest.
The transaction strengthens Rallybio’s liquidity with $7.5 million in equity that can be monetised, de-risks ongoing ENPP1 development costs, and leaves upside through contingent consideration and royalties. However, future value now depends on milestones achieved by Recursion, and Rallybio forgoes direct participation in the JV’s long-term upside.
Rallybio (NASDAQ:RLYB) filed an 8-K announcing a new employment agreement with Chief Medical Officer Steven Ryder, M.D.
Key terms
- Base salary: $531,227
- Annual target bonus: 40% of salary
- Initial one-year term with automatic one-year renewals
- Standard severance: 12 months salary, prior bonus and up to 12 months COBRA
- Change-in-control severance: 1.5× salary + target bonus, 18 months COBRA and full vesting of time-based equity
Severance requires a release of claims; a 12-month non-compete and non-solicitation applies. No other operational or financial updates were disclosed.